Tzu-Yu Chen & Thai-Yen Ling, Ph.D.
Department and Graduate Institute of Pharmacology, College of Medicine, National Taiwan University, Taipei, Taiwan

Introduction

Since the development of induced pluripotent stem cell (iPSC) technology by Yamanaka and colleagues in 2006, regenerative medicine has undergone a remarkable transformation. Unlike embryonic stem cells, iPSCs are generated by reprogramming adult somatic cells into pluripotent cells, thereby avoiding ethical concerns associated with embryo use while retaining the capacity to differentiate into multiple cell types [1]. Consequently, iPSCs have become one of the most promising platforms for regenerative medicine and cell-based therapies. During the past two decades, considerable efforts have focused on translating iPSC technology into clinical applications for neurodegenerative disorders, retinal diseases, cardiovascular diseases, and diabetes. However, challenges including manufacturing consistency, tumorigenicity, immune rejection, and regulatory approval have limited the number of clinically approved iPSC-derived products [2].

Japan has played a leading role in the clinical translation of iPSC technology through continuous governmental support, the establishment of HLA-matched iPSC stock programs, and the development of dedicated regulatory pathways for regenerative medicine [3]. Against this background, AMCHEPRY® (raguneprocel), developed jointly by Sumitomo Pharma and the Center for iPS Cell Research and Application (CiRA), became the first approved iPSC-derived dopaminergic progenitor cell therapy for Parkinson’s disease in Japan in 2026[3]. Its approval represents not only a milestone in regenerative medicine but also a paradigm shift from symptomatic treatment toward cell replacement therapy.

Unlike conventional pharmacological therapies that temporarily restore dopamine levels, AMCHEPRY® delivers iPSC-derived dopaminergic progenitor cells directly into the striatum, aiming to replace degenerated neurons, reconstruct neural circuits, and achieve sustained functional recovery [4]. Therefore, the significance of AMCHEPRY® extends beyond the approval of a novel therapeutic product and highlights the clinical feasibility of iPSC-based regenerative medicine.

Parkinson’s Disease (PD)

Parkinson’s disease is the second most common neurodegenerative disorder worldwide and one of the fastest-growing neurological diseases associated with population aging [5]. It is estimated that more than 25 million people currently live with PD globally, and the prevalence is expected to more than double by 2050 [6]. In addition to progressive motor disability, PD imposes substantial socioeconomic and healthcare burdens.

The hallmark pathology of PD is the progressive degeneration of dopaminergic neurons within the substantia nigra pars compacta, resulting in dopamine depletion in the nigrostriatal pathway. Reduced dopamine disrupts basal ganglia circuitry, ultimately leading to the characteristic motor symptoms of bradykinesia, resting tremor, rigidity, and postural instability. Because clinical manifestations usually become apparent only after approximately half of dopaminergic neurons have already been lost, substantial neurodegeneration has typically occurred by the time of diagnosis [7].

In addition to neuronal loss, abnormal aggregation of α-synuclein represents another pathological hallmark of PD. Misfolded α-synuclein oligomers induce mitochondrial dysfunction, oxidative stress, impaired protein degradation, and chronic neuroinflammation, thereby accelerating neuronal degeneration. Increasing evidence also suggests that α-synuclein may spread through a prion-like mechanism, contributing to disease progression throughout interconnected neural networks. Consequently, PD is now recognized as a multifactorial neurodegenerative disorder involving protein misfolding, neuroinflammation, mitochondrial dysfunction, and impaired cellular homeostasis, rather than merely a dopamine-deficiency syndrome [8,9].

Besides motor dysfunction, patients frequently experience non-motor manifestations including hyposmia, constipation, sleep disturbances, autonomic dysfunction, depression, anxiety, and cognitive impairment. Many of these symptoms precede motor manifestations by several years, highlighting the prolonged prodromal phase of PD and emphasizing the need for disease-modifying therapies capable of intervening before extensive neuronal loss occurs [8,9].

Current Therapeutic Strategies and Their Limitations

Levodopa has remained the cornerstone of Parkinson’s disease (PD) treatment since its introduction in the 1960s [10]. After crossing the blood–brain barrier, levodopa is converted into dopamine and effectively alleviates motor symptoms, particularly bradykinesia and rigidity. To improve therapeutic efficacy and reduce peripheral metabolism, levodopa is commonly administered with carbidopa or benserazide and combined with dopamine agonists, monoamine oxidase-B (MAO-B) inhibitors, or catechol-O-methyltransferase (COMT) inhibitors. Nevertheless, long-term treatment is frequently complicated by motor fluctuations, dyskinesia, and the “on–off” phenomenon, which gradually diminish clinical benefits [11].

For patients with inadequate medical control, deep brain stimulation (DBS) has become an established surgical option. Electrical stimulation of the subthalamic nucleus or globus pallidus interna can improve motor symptoms and reduce medication requirements. However, neither pharmacological therapy nor DBS prevents the progressive degeneration of dopaminergic neurons, and both have limited effects on non-motor manifestations such as cognitive decline, autonomic dysfunction, and gait impairment [12].

Recent therapeutic development has shifted toward disease-modifying approaches, including anti-α-synuclein immunotherapy, gene therapy, RNA-based therapeutics, and small molecules targeting protein aggregation [13]. Although promising in preclinical studies, most candidates have yet to demonstrate significant clinical benefits in large-scale trials. Consequently, current therapies remain primarily symptomatic rather than restorative.

These limitations have renewed interest in cell replacement therapy. Early transplantation of fetal ventral mesencephalic tissue demonstrated proof-of-concept but was hindered by ethical concerns, limited tissue availability, and inconsistent outcomes. The emergence of induced pluripotent stem cell technology has largely overcome these obstacles by providing a renewable and standardized cell source [14].

Current strategies preferentially utilize iPSC-derived dopaminergic progenitor cells rather than mature neurons, as progenitor cells exhibit superior survival, integration, and functional maturation after transplantation. This scientific foundation ultimately led to the development of AMCHEPRY®, the first clinically approved iPSC-derived dopaminergic progenitor cell therapy for Parkinson’s disease. AMCHEPRY® is an allogeneic iPSC-derived dopaminergic progenitor cell therapy developed by Sumitomo Pharma for the treatment of Parkinson’s disease. It is the first commercially approved iPSC-derived regenerative medicine product for PD and is administered through stereotactic bilateral transplantation into the putamen. Unlike conventional pharmacological therapies that temporarily restore dopamine levels, AMCHEPRY® aims to replace degenerated dopaminergic neurons and reconstruct the nigrostriatal pathway through cell replacement therapy [4]. The product consists of clinical-grade ventral midbrain dopaminergic progenitor cells manufactured under good manufacturing practice (GMP) conditions using HLA-matched allogeneic iPSC cell lines.

Development and Clinical Translation of AMCHEPRY®

AMCHEPRY® is the world’s first approved iPSC-derived dopaminergic progenitor cell therapy for Parkinson’s disease. Its development originated from long-term research conducted at the CiRA, Kyoto University, which established robust protocols for generating clinical-grade ventral midbrain dopaminergic progenitor cells from human iPSCs. Compared with mature dopaminergic neurons, these progenitor cells exhibit greater survival, neuronal maturation, and integration capacity after transplantation, making them the preferred cell source for PD cell replacement therapy.

To facilitate clinical translation, Sumitomo Pharma collaborated with CiRA to establish a standardized GMP production platform. The manufacturing process includes iPSC bank establishment, neural differentiation, cell purification, and comprehensive quality control, including sterility testing, chromosomal stability, cell identity, viability, and residual undifferentiated cell analysis to minimize tumorigenic risk. Consistent with the concept that “the process is the product,” stringent manufacturing control is considered essential for ensuring product quality and safety [4].

Unlike conventional pharmacological therapies, AMCHEPRY® is administered through stereotactic neurosurgery rather than oral or intravenous delivery. iPSC-derived dopaminergic progenitor cells are transplanted bilaterally into the putamen, where they progressively differentiate into mature dopaminergic neurons, express tyrosine hydroxylase (TH), dopamine transporter (DAT), and vesicular monoamine transporter 2 (VMAT2), and subsequently establish functional synaptic connections with host neurons. Besides dopamine replacement, transplanted cells may also secrete neurotrophic factors such as brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF), potentially promoting neuronal survival and neural plasticity [4].

Preclinical studies in non-human primates demonstrated long-term graft survival, neuronal maturation, functional motor improvement, and an absence of tumor formation, providing the rationale for subsequent clinical studies. Early phase I/II clinical trials evaluated the safety and preliminary efficacy of bilateral stereotactic transplantation in patients with moderate to advanced PD. Clinical outcomes were assessed using the Unified Parkinson’s Disease Rating Scale (UPDRS), magnetic resonance imaging (MRI), positron emission tomography (PET), and daily motor fluctuations. Initial results demonstrated favorable safety profiles without product-related serious adverse events or tumor formation. Improvements in UPDRS motor scores, reduced daily off-time, and increased dopaminergic activity detected by PET suggest successful graft survival and functional integration. Nevertheless, because current clinical evidence is based on relatively small cohorts with limited follow-up, long-term efficacy and durability remain to be established through larger post-marketing studies [4].

As the first commercially available iPSC-derived therapy for PD, AMCHEPRY® represents a milestone in regenerative medicine by shifting treatment from symptomatic dopamine replacement toward neuronal reconstruction. Despite encouraging early results, long-term monitoring of graft survival, immune compatibility, tumorigenicity, and sustained clinical benefit remains essential to fully define its therapeutic value.

Clinical Perspective and Future Directions

The approval of AMCHEPRY® highlights Japan’s leadership in regenerative medicine. In addition to scientific advances in iPSC technology, Japan has established a dedicated regulatory framework for regenerative medical products through the Pharmaceuticals and Medical Devices Act (PMD Act) and the Act on the Safety of Regenerative Medicine. Unlike conventional pharmaceuticals, regenerative therapies may receive conditional and time-limited approval based on preliminary evidence of safety and probable clinical benefit, followed by post-marketing surveillance to confirm long-term efficacy and safety. This regulatory pathway has accelerated clinical translation while maintaining continuous safety monitoring.

As the first approved iPSC-derived therapy for Parkinson’s disease, AMCHEPRY® represents an important milestone in translating stem cell research into clinical practice. Its approval demonstrates that standardized iPSC manufacturing, GMP production, and rigorous quality control can support commercialization of regenerative medicine products. More importantly, it shifts the therapeutic concept of Parkinson’s disease from symptomatic dopamine replacement toward neuronal reconstruction through cell replacement therapy [4].

Nevertheless, several challenges remain. Long-term graft survival, immune compatibility, durability of clinical benefit, and potential late-onset adverse events require continued investigation through post-marketing studies [15]. In addition, Parkinson’s disease involves complex pathological processes beyond dopaminergic neuron loss, including α-synuclein aggregation, neuroinflammation, and mitochondrial dysfunction, suggesting that cell replacement alone may not completely halt disease progression.

Despite these limitations, AMCHEPRY® establishes a new paradigm for regenerative medicine and provides a foundation for future iPSC-derived therapies targeting neurological and other degenerative diseases. Continued advances in stem cell biology, manufacturing technologies, and clinical evaluation are expected to further expand the role of regenerative medicine in clinical practice.

References

• Cerneckis, J., Cai, H., & Shi, Y. (2024). Induced pluripotent stem cells (iPSCs): molecular mechanisms of induction and applications. Signal Transduction and Targeted Therapy, 9(1), 112.
• Omole, A. E., & Fakoya, A. O. J. (2018). Ten years of progress and promise of induced pluripotent stem cells: historical origins, characteristics, mechanisms, limitations, and potential applications. PeerJ, 6, e4370.
• Choi, K. S. N., & Liu, W. B. (2025). Driving the future of iPS-cell-based therapy in Japan: government strategies, regulatory review and clinical development. Drug Discovery Today, 104562.
• Sawamoto, N., Doi, D., Nakanishi, E., Sawamura, M., Kikuchi, T., Yamakado, H., … & Takahashi, J. (2025). Phase I/II trial of iPS-cell-derived dopaminergic cells for Parkinson’s disease. Nature, 641(8064), 971-977.
• Li, M., Ye, X., Huang, Z., Ye, L., & Chen, C. (2025). Global burden of Parkinson’s disease from 1990 to 2021: a population-based study. BMJ open, 15(4), e095610.
• Yang, H., Pu, L., Zhao, T., Pan, L., Jiang, Y., Han, L., & Guan, Q. (2026). The burden of Parkinson’s disease based on the GBD 2021. International Journal of Public Health, 71, 1608863.
• Zeng, Z., Roussakis, A. A., Lao-Kaim, N. P., & Piccini, P. (2020). Astrocytes in Parkinson’s disease: from preclinical assays to in vivo imaging and therapeutic probes. Neurobiology of aging, 95, 264-270.
• Yang, K., Lv, Z., Zhao, W., Lai, G., Zheng, C., Qi, F., … & Zheng, W. (2024). The potential of natural products to inhibit abnormal aggregation of α-Synuclein in the treatment of Parkinson’s disease. Frontiers in Pharmacology, 15, 1468850.
• Schapira, A. H., Chaudhuri, K. R., & Jenner, P. (2017). Non-motor features of Parkinson disease. Nature Reviews Neuroscience, 18(7), 435-450.
• Katzenschlager, R., & Lees, A. J. (2002). Treatment of Parkinson’s disease: levodopa as the first choice. Journal of neurology, 249(Suppl 2), ii19-ii24.
• Riederer, P., Strobel, S., Nagatsu, T., Watanabe, H., Chen, X., Löschmann, P. A., … & Monoranu, C. M. (2025). Levodopa treatment: impacts and mechanisms throughout Parkinson’s disease progression: P. Riederer et al. Journal of Neural Transmission, 132(6), 743-779.
• Mainardi, M., Ciprietti, D., Pilleri, M., Bonato, G., Weis, L., Cianci, V., … & Antonini, A. (2024). Deep brain stimulation of globus pallidus internus and subthalamic nucleus in Parkinson’s disease: a multicenter, retrospective study of efficacy and safety. Neurological sciences, 45(1), 177-185.
• Zhan, X., Wen, G., Wu, X., & Li, J. Y. (2025). Immunization targeting diseased proteins in synucleinopathy and tauopathy: insights from clinical trials. Translational Neurodegeneration, 14(1), 33.
• Harary, P. M., Jgamadze, D., Kim, J., Wolf, J. A., Song, H., Ming, G. L., … & Chen, H. I. (2023). Cell replacement therapy for brain repair: recent progress and remaining challenges for treating Parkinson’s disease and cortical injury. Brain Sciences, 13(12), 1654.
• Marshall, A. (2026). World’s first two iPSC therapies in Japan. nature biotechnology, 44, 495-502.